Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Next-generation pneumococcal vaccine (Adult)
- Development stage
- Preclinical
- Lead developer
- SK bioscience
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The next-generation pneumococcal vaccine (Adult) is a pneumococcal conjugate vaccine (PCV) being developed by SK bioscience in collaboration with Sanofi. It is designed to provide broader protection against Streptococcus pneumoniae than currently licensed vaccines by targeting a wider range of serotypes responsible for invasive pneumococcal disease (IPD) in adult populations. As a conjugate vaccine, it works by stimulating the immune system to recognize and respond to the capsular polysaccharides of the bacteria, which are conjugated to a carrier protein to enhance immunogenicity, particularly in older adults. This program is distinct from the companies' 21-valent pediatric vaccine candidate (GBP410) and is currently in the preclinical stage of development.
- Other names
- Next-generation pneumococcal conjugate vaccine (Adult)
Beyond the preview
Go deeper on Next-generation pneumococcal vaccine (Adult).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Next-generation pneumococcal vaccine (Adult).